Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $7.2800 (0.97%) ($6.5800 - $7.3500) on Tue. Nov. 10, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.51% (three month average) | RSI | 45 | Latest Price | $7.2800(0.97%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -2.5% a day on average for past five trading days. | Weekly Trend | HTBX declines -2.7% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(34%) ARKK(33%) XBI(33%) BLOK(32%) IPO(31%) | Factors Impacting HTBX price | HTBX will decline at least -3.255% in a week (0% probabilities). VXX(-20%) VIXM(-19%) UUP(-15%) XLU(-4%) XLP(-2%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.255% (StdDev 6.51%) | Hourly BBV | -0.2 () | Intraday Trend | 1% | | | |
|
1 - 5 Day Possible Target | $-5.15(-170.74%) | Resistance Level | $8.27 | 5 Day Moving Average | $7.77(-6.31%) | 10 Day Moving Average | $8.01(-9.11%) | 20 Day Moving Average | $8.27(-11.97%) | To recent high | -50.7% | To recent low | 2% | Market Cap | $801m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |